| Sunitinib-induced reversible posterior leukoencephalopathy syndrome after rifampin discontinuation |
|
Mi-Jung Kim, Hee Jun Kim, Hyun-Mi Bae, Sung Hoon Sim, Jeong-Ok Lee, Yongjun Cha, Se-Hoon Lee |
|
|
| Rifampin 중단으로 촉발된 sunitinib에 의한 reversible posterior leukoencephalopathy syndrome (RPLS) 1예 |
|
김미정, 김희준, 배현미, 심성훈, 이정옥, 차용준, 이세훈 |
|
|
|
|
|
|
| Abstract |
|
Sunitinib is an oral tyrosine kinase inhibitor with anti-angiogenic activity that is used for the treatment of advanced renal cell carcinoma and advanced gastrointestinal stromal tumors after failure on imatinib. The most common adverse effects of sunitinib are fatigue, diarrhea, nausea, stomatitis, hypertension, hand-foot syndrome, and cytopenia. Sunitinib was recently reported to be associated with reversible posterior leukoencephalopathy syndrome (RPLS). Here, we report the case of a 76-year-old woman with sunitinib-induced RPLS that developed after rifampin discontinuation. |
| Key Words:
Sunitinib; Posterior leukoencephalopathy syndrome; Carcinoma; Renal cell. |
|
PDF Links
Full text via DOI
Download Citation
